Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press12010.17650/1994-4098-2012-0-3-4-88-92GYNECOLOGY. PROBLEMГИНЕКОЛОГИЯ. ПРОБЛЕМАManagement of ovarian carcinosarcomas (review of literature)Лечение карциносарком яичников (обзор литературы)GritsaiA. N.ГрицайА. Н.
Russian Federation
ShvachkoS. A.ШвачкоС. А.
Russian Federation
sashvachko@gmail.comLazarevaN. I.ЛазареваН. И.
Russian Federation
PetersonS. B.ПетерсонС. Б.
Russian Federation
NikolaevA. P.НиколаевА. П.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, МоскваDepartment of Oncology, Faculty of Therapeutics, Russian National Research Medical University, Ministry of Health of Russia, Moscowкафедра онкологии лечебного факультета ГОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва240920123-4889224072014240720142012https://ojrs.abvpress.ru/ojrs/article/view/120

This review contains data on an aetiology, features of a clinical presentations and modern approaches in diagnostics and treatment of ovarian carcinosarcomas.

В обзоре освещаются этиология, особенности клинического течения и современные подходы к диагностике и лечению злокачественных смешанных мюллеровских опухолей яичников.

ovarian sarcomascarcinosarcomamalignant mixed mullerian tumoursсаркома яичниковкарциносаркомасмешанная мюллеровская опухоль1. Лазарева Н.И. Злокачественные мезенхимальные опухоли женских половых органов (клиника, диагностика, лечение, факторы прогноза). Дис. ... докт. мед. наук. М., 2003. 268 с.Лазарева Н.И. Злокачественные мезенхимальные опухоли женских половых органов (клиника, диагностика, лечение, факторы прогноза). Дис. ... докт. мед. наук. М., 2003. 268 с.2. Anderson B., Turner D.A., Benda J. Ovarian sarcoma. Gynecol Oncol 1987;26:183–92.Anderson B., Turner D.A., Benda J. Ovarian sarcoma. Gynecol Oncol 1987;26:183–92.3. Anderson W., Young D.E., Peters W.A. et al. Platinum based combination chemotherapy for malignant mixed mesodermal tumours of the ovary. Gynecol Oncol 1989;32:319–22.Anderson W., Young D.E., Peters W.A. et al. Platinum based combination chemotherapy for malignant mixed mesodermal tumours of the ovary. Gynecol Oncol 1989;32:319–22.4. Berek J.S., Hacker N.F. Practical Gynecologic Oncology. Fourth edition. Lippincott Williams and Wilkins, 2005. Pp. 511–41.Berek J.S., Hacker N.F. Practical Gynecologic Oncology. Fourth edition. Lippincott Williams and Wilkins, 2005. Pp. 511–41.5. Berek J.S., Hacker N.F. Sarcomas of the female genital tract. In: F.R. Eilber et al. The Soft Tissue Sarcomas. Orlando: Grune&Stratton, 1987. Pp. 229–38.Berek J.S., Hacker N.F. Sarcomas of the female genital tract. In: F.R. Eilber et al. The Soft Tissue Sarcomas. Orlando: Grune&Stratton, 1987. Pp. 229–38.6. Baker T.R., Piver M.S., Caglar H., Piedmonte M. Prospective trial of cisplatin, adriamycin, dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary. Am J Clin Oncol 1991;14:246–50.Baker T.R., Piver M.S., Caglar H., Piedmonte M. Prospective trial of cisplatin, adriamycin, dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary. Am J Clin Oncol 1991;14:246–50.7. Brown E., Stewart M., Rye T. et al. Carcinosarcoma of the ovary: 19 years of prospective data from single center. Cancer 2004;100:2148–53.Brown E., Stewart M., Rye T. et al. Carcinosarcoma of the ovary: 19 years of prospective data from single center. Cancer 2004;100:2148–53.8. Calvert A.H., Newall D.R., Grumbell L.A. et al. Carboplatin dosage prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–56.Calvert A.H., Newall D.R., Grumbell L.A. et al. Carboplatin dosage prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–56.9. Carlson J.A., Edwards C., Wharton J.T. et al. Mixed mesodermal sarcoma of ovary: Treatment with combination radiation therapy and chemotherapy. Cancer 1983;52:1473–7.Carlson J.A., Edwards C., Wharton J.T. et al. Mixed mesodermal sarcoma of ovary: Treatment with combination radiation therapy and chemotherapy. Cancer 1983;52:1473–7.10. Chang J., Sharpe J.C. , A'Hern R.P. et al. Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients. Annals of Oncology 1995;6:755–8.Chang J., Sharpe J.C. , A'Hern R.P. et al. Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients. Annals of Oncology 1995;6:755–8.11. Cicin I., Pinar S., Yesim E. et al. Ovarian carcinosarcomas: Clinicopathological prognosis factors and evaluation of chemotherapy regimens containing platinum. Gynecologic Oncology 2008;108(1):136–40.Cicin I., Pinar S., Yesim E. et al. Ovarian carcinosarcomas: Clinicopathological prognosis factors and evaluation of chemotherapy regimens containing platinum. Gynecologic Oncology 2008;108(1):136–40.12. Clement P.B., Scully R.E. Mullerian adenosarcoma of the uterus. A clinicopathologic analysis often cases of adistinctive type of mullerian mixed tumor. Cancer 1974;34:1138–49.Clement P.B., Scully R.E. Mullerian adenosarcoma of the uterus. A clinicopathologic analysis often cases of adistinctive type of mullerian mixed tumor. Cancer 1974;34:1138–49.13. Crotzer D.R., Wolf J.K., Jenkins A.D. et al. A pilot study of cisplatine, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Proc Am Soc Clin Oncol 2003;24:474.Crotzer D.R., Wolf J.K., Jenkins A.D. et al. A pilot study of cisplatine, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Proc Am Soc Clin Oncol 2003;24:474.14. Czernobilsky B., Gillespie J.J., Roth L.M. Adenosarcoma of the ovary A light-and electron-microscopic study with review of the literature. Diagn Gynecol Obstet 1982; 4:25–36.Czernobilsky B., Gillespie J.J., Roth L.M. Adenosarcoma of the ovary A light-and electron-microscopic study with review of the literature. Diagn Gynecol Obstet 1982; 4:25–36.15. Dass K.K., Biscotti C.V., Webster K., Saxton J.P. Malignant mixed mullerian tumours of the ovary. An analysis of two long term survivors. Am J Clin Oncol 1993;16(4):346–9.Dass K.K., Biscotti C.V., Webster K., Saxton J.P. Malignant mixed mullerian tumours of the ovary. An analysis of two long term survivors. Am J Clin Oncol 1993;16(4):346–9.16. Dehner L.P., Norris H.J., Taylor H.B. Carcinosarcomas and mixed mesodermal tumours of the ovary. Cancer 1971;27:207–16.Dehner L.P., Norris H.J., Taylor H.B. Carcinosarcomas and mixed mesodermal tumours of the ovary. Cancer 1971;27:207–16.17. Dictor M. Malignant mixed mesodermal tumour of the ovary: A report of 22 cases. Obstet Gynecol 1985;65:720–4.Dictor M. Malignant mixed mesodermal tumour of the ovary: A report of 22 cases. Obstet Gynecol 1985;65:720–4.18. Eichhorn J.H., Young R.H., Clement P.B., Scully R.E. Mesodermal (mullerian) adenosarcoma of the ovary: a clinico-pathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol 2002;26:1243–58.Eichhorn J.H., Young R.H., Clement P.B., Scully R.E. Mesodermal (mullerian) adenosarcoma of the ovary: a clinico-pathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol 2002;26:1243–58.19. Garamvoelgyi E., Guillou L., Gebhard S. et al. Primary malignant mixed mullerian tumour (metaplastic carcinoma) of the female peritoneum. Cancer 1994;74(3):854–63.Garamvoelgyi E., Guillou L., Gebhard S. et al. Primary malignant mixed mullerian tumour (metaplastic carcinoma) of the female peritoneum. Cancer 1994;74(3):854–63.20. Geisler J.P., Wiemann M.C., Miller G.A. et al. Estrogen and progesterone receptors in malignant mixed mesodermal tumors of the ovary. J Surg Oncol 1995;59:45–7.Geisler J.P., Wiemann M.C., Miller G.A. et al. Estrogen and progesterone receptors in malignant mixed mesodermal tumors of the ovary. J Surg Oncol 1995;59:45–7.21. Hanjani P., Peterson R.O., Lipton S.E., Nolte S.A. Malignant mixed mesodermal tumours of the ovary: Report of eight cases and review of the literature. Obstet Gynecol Surv 1993;38:537–45.Hanjani P., Peterson R.O., Lipton S.E., Nolte S.A. Malignant mixed mesodermal tumours of the ovary: Report of eight cases and review of the literature. Obstet Gynecol Surv 1993;38:537–45.22. Le T., Krepart G.V., Lotocki R.J., Heywood M.S. Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20 year experience. Gynecol Oncol 1997; 65:237–40.Le T., Krepart G.V., Lotocki R.J., Heywood M.S. Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20 year experience. Gynecol Oncol 1997; 65:237–40.23. Leiser A.L., Chi D.S., Ishill N.M., Tew W.P. Carcinosarcoma of the ovary treated with platinum and taxane: The memorial Sloan- Kettering Cancer Center experience. Gynecologic Oncology 2007;105:651–61.Leiser A.L., Chi D.S., Ishill N.M., Tew W.P. Carcinosarcoma of the ovary treated with platinum and taxane: The memorial Sloan- Kettering Cancer Center experience. Gynecologic Oncology 2007;105:651–61.24. Lele S.B., Piver M.S., Barlow J.J. Chemotherapy in the management of mixed mesodermal tumours of the ovary. Gynecol Oncol 1980;10:298–302.Lele S.B., Piver M.S., Barlow J.J. Chemotherapy in the management of mixed mesodermal tumours of the ovary. Gynecol Oncol 1980;10:298–302.25. Mano M.S., Rosa D.D., Azambuja E. et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 2007;17:316–24.Mano M.S., Rosa D.D., Azambuja E. et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 2007;17:316–24.26. Marshall R.J. Mixed mullerian tumour of the gynecological system other than endometrial tumours. In: Williams C., Krikonan J.G., Green M.R., Raghaven D. (eds): Textbook of Uncommon Cancers. Chichester, 1988.Marshall R.J. Mixed mullerian tumour of the gynecological system other than endometrial tumours. In: Williams C., Krikonan J.G., Green M.R., Raghaven D. (eds): Textbook of Uncommon Cancers. Chichester, 1988.27. Mok J.E., Kim Y.M., Jung M.H. et al. Malignant mixed Mullerian tumors of the ovary: experience with citoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer 2006;16:101–5.Mok J.E., Kim Y.M., Jung M.H. et al. Malignant mixed Mullerian tumors of the ovary: experience with citoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer 2006;16:101–5.28. Morrow C.P., Ablaing G., Brady L.W. et al. A clinical pathological study of 30 cases of malignant mixed mullerian tumors: A gynecologic oncology group study. Gynecol Oncol 1984;18:278–92.Morrow C.P., Ablaing G., Brady L.W. et al. A clinical pathological study of 30 cases of malignant mixed mullerian tumors: A gynecologic oncology group study. Gynecol Oncol 1984;18:278–92.29. Morrow C.P., Bundy B., Hoffman J. et al. Adriamycin chemotherapy for malignant mixed mesodermal tumour of ovary. Am J Clin Oncol 1986;9:24–6.Morrow C.P., Bundy B., Hoffman J. et al. Adriamycin chemotherapy for malignant mixed mesodermal tumour of ovary. Am J Clin Oncol 1986;9:24–6.30. Plaxe S.C., Dottino P.R., Goodman H.M. et al. Clinical features of advanced ovarian mixed mullerian tumours and treatment with doxorubicin and cisplatin chemotherapy. Gynecol Oncol 1990;37:244–9.Plaxe S.C., Dottino P.R., Goodman H.M. et al. Clinical features of advanced ovarian mixed mullerian tumours and treatment with doxorubicin and cisplatin chemotherapy. Gynecol Oncol 1990;37:244–9.31. Prendiville J., Murply D., Rennision J. et al. Carcinosarcoma of the ovary treated over a ten year period at the Christie Hospital. Int J Gynecol Cancer 1994;4(3):200–5.Prendiville J., Murply D., Rennision J. et al. Carcinosarcoma of the ovary treated over a ten year period at the Christie Hospital. Int J Gynecol Cancer 1994;4(3):200–5.32. Raspollini M.R., Susini T., Ammuni G. et al. Expression and amplification of HER-2/ neu oncogene in uterine carcinosarcomas a marker for potential molecularly targeted treatment? Int J Gynecol Cancer 2006; 16:416–22.Raspollini M.R., Susini T., Ammuni G. et al. Expression and amplification of HER-2/ neu oncogene in uterine carcinosarcomas a marker for potential molecularly targeted treatment? Int J Gynecol Cancer 2006; 16:416–22.33. Rutledge T.L., Gold M.A., McMeekin D.S. et al. Carcinosarcoma of ovary – a case series. Gynecol Oncol 2006;100;128–32.Rutledge T.L., Gold M.A., McMeekin D.S. et al. Carcinosarcoma of ovary – a case series. Gynecol Oncol 2006;100;128–32.34. Sawada M., Tsuda H., Kimura M. et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci 2003;94(11):986–91.Sawada M., Tsuda H., Kimura M. et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci 2003;94(11):986–91.35. Silasi D.-A., Illuzzi J.L., Kelly M.G. et al. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008;18:22–9.Silasi D.-A., Illuzzi J.L., Kelly M.G. et al. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008;18:22–9.36. Silverberg S.G., Kurman R.J. Atlas of Tumour Pathology, 3rd series Fascicle 3. Washington DC: Armed Forces Institute of Pathology, 1991. P. 166.Silverberg S.G., Kurman R.J. Atlas of Tumour Pathology, 3rd series Fascicle 3. Washington DC: Armed Forces Institute of Pathology, 1991. P. 166.37. Sit A.S., Price F.V., Kelley J.L. et al. Chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecol Oncol 2000;79:196–200.Sit A.S., Price F.V., Kelley J.L. et al. Chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecol Oncol 2000;79:196–200.38. Simon S.R., Wang S.E., Uhl M., Shackney S. Complete response of carcinosarcoma of ovary to therapy with doxorubicin, ifosfamide, and dacarbazine. Gynecol Oncol 1991;41:161–6.Simon S.R., Wang S.E., Uhl M., Shackney S. Complete response of carcinosarcoma of ovary to therapy with doxorubicin, ifosfamide, and dacarbazine. Gynecol Oncol 1991;41:161–6.39. Sood A.K., Sorosky J.I., Gelder M.S. et al. Primary ovarian sarcoma: Analysis of prognostic variables and the role of surgical cytoreduction. Cancer 1998;82(9):1731–7.Sood A.K., Sorosky J.I., Gelder M.S. et al. Primary ovarian sarcoma: Analysis of prognostic variables and the role of surgical cytoreduction. Cancer 1998;82(9):1731–7.40. Thigpen J., Blessing J.A., DeGeest K. et al., Gynecologic Oncology Group. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 2004;93:336–9.Thigpen J., Blessing J.A., DeGeest K. et al., Gynecologic Oncology Group. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 2004;93:336–9.41. Zorzou M.P., Markaki S., Rodolakis S. et al. Clinicopathological features of ovarian carcinosarcomas: a single institution experience. Gynecol Oncol 2005;96:136–42.Zorzou M.P., Markaki S., Rodolakis S. et al. Clinicopathological features of ovarian carcinosarcomas: a single institution experience. Gynecol Oncol 2005;96:136–42.